SlideShare a Scribd company logo
1 of 1
Download to read offline
THE CHANGING FACE
OF LUNG CANCER IN 2013
LUNG CANCER
ACCOUNTS FOR

14%

of all new
cancer
cases1

ABOUT 228,190
NEW CASES OF
LUNG CANCER
WILL BE DIAGNOSED1

About 2 out of 3
people diagnosed
with lung cancer
are 65 or older1
Fewer than 2%
of all cases are
found in people
younger than 451

118,080 men

THE AVERAGE AGE AT THE
1
TIME OF DIAGNOSIS IS ABOUT
THERE WILL BE
AN ESTIMATED
159,480 DEATHS
FROM LUNG
CANCER1
Accounting
for 27% of
all cancer
deaths1

110,110 women

71.1

THERE ARE
2 TYPES OF
LUNG CANCER
Non-small cell lung cancer (NSCLC):
About 85-90%
of lung cancers1

Small cell lung cancer (SCLC):
About 10% to 15%
of lung cancers1

References:
1. American Cancer Society. Lung Cancer (Non-Small Cell). Available at:
http://www.cancer.org/cancer/lungcancer-non-smallcell/detailedguide/non-small-cell-lung-cancer-key-statistics.
Last Accessed March 1, 2013.
OC553716PRB

More Related Content

Viewers also liked

Spatially resolved characterization of capping using nondestructive ultrasoni...
Spatially resolved characterization of capping using nondestructive ultrasoni...Spatially resolved characterization of capping using nondestructive ultrasoni...
Spatially resolved characterization of capping using nondestructive ultrasoni...Boehringer Ingelheim Pharmaceuticals, Inc.
 
Solid Form Aspects of Excipients and Their Influence on Formulation and Process
Solid Form Aspects of Excipients and Their Influence on Formulation and ProcessSolid Form Aspects of Excipients and Their Influence on Formulation and Process
Solid Form Aspects of Excipients and Their Influence on Formulation and ProcessBoehringer Ingelheim Pharmaceuticals, Inc.
 
Partnerships for Drug Delivery
Partnerships for Drug DeliveryPartnerships for Drug Delivery
Partnerships for Drug Deliverycassie111
 
George Heidgerken, Global Head of Animal Health, Boehringer Ingelheim
George Heidgerken, Global Head of Animal Health, Boehringer IngelheimGeorge Heidgerken, Global Head of Animal Health, Boehringer Ingelheim
George Heidgerken, Global Head of Animal Health, Boehringer IngelheimKisaco Research
 
"Protecting Patients from Counterfeit Medicines," Congressional Briefing, Mar...
"Protecting Patients from Counterfeit Medicines," Congressional Briefing, Mar..."Protecting Patients from Counterfeit Medicines," Congressional Briefing, Mar...
"Protecting Patients from Counterfeit Medicines," Congressional Briefing, Mar...The Partnership For Safe Medicines
 
High Tech-High Touch RPO: What the Doctor Ordered for Boehringer Ingelheim
High Tech-High Touch RPO: What the Doctor Ordered for Boehringer IngelheimHigh Tech-High Touch RPO: What the Doctor Ordered for Boehringer Ingelheim
High Tech-High Touch RPO: What the Doctor Ordered for Boehringer IngelheimCielo
 
Q3 2016 Investor Conference Call Presentation
Q3 2016 Investor Conference Call PresentationQ3 2016 Investor Conference Call Presentation
Q3 2016 Investor Conference Call PresentationBayer
 
Bayer AG Meet Management 2016 Investor Handout
Bayer AG Meet Management 2016 Investor HandoutBayer AG Meet Management 2016 Investor Handout
Bayer AG Meet Management 2016 Investor HandoutBayer
 
Bayer HealthCare Overview
Bayer HealthCare OverviewBayer HealthCare Overview
Bayer HealthCare Overviewbhcbelgium
 
Global Biopharmaceutical Contract Manufacturing Market - Qualitative and Quan...
Global Biopharmaceutical Contract Manufacturing Market - Qualitative and Quan...Global Biopharmaceutical Contract Manufacturing Market - Qualitative and Quan...
Global Biopharmaceutical Contract Manufacturing Market - Qualitative and Quan...Aiswariya Chidambaram
 
Explaining Accountable Care Organizations (ACOs): Key Strategies for Educatin...
Explaining Accountable Care Organizations (ACOs): Key Strategies for Educatin...Explaining Accountable Care Organizations (ACOs): Key Strategies for Educatin...
Explaining Accountable Care Organizations (ACOs): Key Strategies for Educatin...Boehringer Ingelheim Pharmaceuticals, Inc.
 

Viewers also liked (19)

Boehringer Ingelheim Cares Foundation Giving Report
Boehringer Ingelheim Cares Foundation Giving ReportBoehringer Ingelheim Cares Foundation Giving Report
Boehringer Ingelheim Cares Foundation Giving Report
 
Spatially resolved characterization of capping using nondestructive ultrasoni...
Spatially resolved characterization of capping using nondestructive ultrasoni...Spatially resolved characterization of capping using nondestructive ultrasoni...
Spatially resolved characterization of capping using nondestructive ultrasoni...
 
Solid Form Aspects of Excipients and Their Influence on Formulation and Process
Solid Form Aspects of Excipients and Their Influence on Formulation and ProcessSolid Form Aspects of Excipients and Their Influence on Formulation and Process
Solid Form Aspects of Excipients and Their Influence on Formulation and Process
 
Organizational Effectiveness 2013 Impact Assessment
Organizational Effectiveness 2013 Impact AssessmentOrganizational Effectiveness 2013 Impact Assessment
Organizational Effectiveness 2013 Impact Assessment
 
Partnerships for Drug Delivery
Partnerships for Drug DeliveryPartnerships for Drug Delivery
Partnerships for Drug Delivery
 
Pharma trends 2012, AUSTRALIA
Pharma trends 2012, AUSTRALIAPharma trends 2012, AUSTRALIA
Pharma trends 2012, AUSTRALIA
 
Aylin
AylinAylin
Aylin
 
George Heidgerken, Global Head of Animal Health, Boehringer Ingelheim
George Heidgerken, Global Head of Animal Health, Boehringer IngelheimGeorge Heidgerken, Global Head of Animal Health, Boehringer Ingelheim
George Heidgerken, Global Head of Animal Health, Boehringer Ingelheim
 
"Protecting Patients from Counterfeit Medicines," Congressional Briefing, Mar...
"Protecting Patients from Counterfeit Medicines," Congressional Briefing, Mar..."Protecting Patients from Counterfeit Medicines," Congressional Briefing, Mar...
"Protecting Patients from Counterfeit Medicines," Congressional Briefing, Mar...
 
High Tech-High Touch RPO: What the Doctor Ordered for Boehringer Ingelheim
High Tech-High Touch RPO: What the Doctor Ordered for Boehringer IngelheimHigh Tech-High Touch RPO: What the Doctor Ordered for Boehringer Ingelheim
High Tech-High Touch RPO: What the Doctor Ordered for Boehringer Ingelheim
 
Q3 2016 Investor Conference Call Presentation
Q3 2016 Investor Conference Call PresentationQ3 2016 Investor Conference Call Presentation
Q3 2016 Investor Conference Call Presentation
 
Bayer AG Meet Management 2016 Investor Handout
Bayer AG Meet Management 2016 Investor HandoutBayer AG Meet Management 2016 Investor Handout
Bayer AG Meet Management 2016 Investor Handout
 
Bayer ppt
Bayer pptBayer ppt
Bayer ppt
 
Bayer HealthCare Overview
Bayer HealthCare OverviewBayer HealthCare Overview
Bayer HealthCare Overview
 
Global Biopharmaceutical Contract Manufacturing Market - Qualitative and Quan...
Global Biopharmaceutical Contract Manufacturing Market - Qualitative and Quan...Global Biopharmaceutical Contract Manufacturing Market - Qualitative and Quan...
Global Biopharmaceutical Contract Manufacturing Market - Qualitative and Quan...
 
Johnson & johnson
Johnson & johnsonJohnson & johnson
Johnson & johnson
 
2012 U.S. Corporate Overview
2012 U.S. Corporate Overview2012 U.S. Corporate Overview
2012 U.S. Corporate Overview
 
Explaining Accountable Care Organizations (ACOs): Key Strategies for Educatin...
Explaining Accountable Care Organizations (ACOs): Key Strategies for Educatin...Explaining Accountable Care Organizations (ACOs): Key Strategies for Educatin...
Explaining Accountable Care Organizations (ACOs): Key Strategies for Educatin...
 
Talent optimization: Its not a one way street
Talent optimization: Its not a one way streetTalent optimization: Its not a one way street
Talent optimization: Its not a one way street
 

Similar to Lung cancer infographic

CES 2016 02 - Lung Cancer
CES 2016 02 - Lung CancerCES 2016 02 - Lung Cancer
CES 2016 02 - Lung CancerMauricio Lema
 
Running Head SMALL-CELL LUNG CANCERSMALL-CELL LUNG CANCER .docx
Running Head SMALL-CELL LUNG CANCERSMALL-CELL LUNG CANCER      .docxRunning Head SMALL-CELL LUNG CANCERSMALL-CELL LUNG CANCER      .docx
Running Head SMALL-CELL LUNG CANCERSMALL-CELL LUNG CANCER .docxagnesdcarey33086
 
Review article...
Review article...Review article...
Review article...Eiman Rana
 
CES2019-02: One hour on lung cancer for medical students
CES2019-02: One hour on lung cancer for medical studentsCES2019-02: One hour on lung cancer for medical students
CES2019-02: One hour on lung cancer for medical studentsMauricio Lema
 
Athanasios Andriopoulos_final (2)
Athanasios Andriopoulos_final (2)Athanasios Andriopoulos_final (2)
Athanasios Andriopoulos_final (2)Thanos Andriopoulos
 
CES2017-02: Lung Cancer
CES2017-02: Lung CancerCES2017-02: Lung Cancer
CES2017-02: Lung CancerMauricio Lema
 
Lung_cancer_presentation.pptx for medical Surgical Nursing
Lung_cancer_presentation.pptx for medical Surgical NursingLung_cancer_presentation.pptx for medical Surgical Nursing
Lung_cancer_presentation.pptx for medical Surgical NursingHari Gobu
 
CES2018-02: Cáncer de pulmón (clases 1 y 2)
CES2018-02: Cáncer de pulmón (clases 1 y 2)CES2018-02: Cáncer de pulmón (clases 1 y 2)
CES2018-02: Cáncer de pulmón (clases 1 y 2)Mauricio Lema
 

Similar to Lung cancer infographic (17)

Lung cancer
Lung cancerLung cancer
Lung cancer
 
CES 2016 02 - Lung Cancer
CES 2016 02 - Lung CancerCES 2016 02 - Lung Cancer
CES 2016 02 - Lung Cancer
 
Running Head SMALL-CELL LUNG CANCERSMALL-CELL LUNG CANCER .docx
Running Head SMALL-CELL LUNG CANCERSMALL-CELL LUNG CANCER      .docxRunning Head SMALL-CELL LUNG CANCERSMALL-CELL LUNG CANCER      .docx
Running Head SMALL-CELL LUNG CANCERSMALL-CELL LUNG CANCER .docx
 
Review article...
Review article...Review article...
Review article...
 
All About Lung Cancer
All  About Lung Cancer All  About Lung Cancer
All About Lung Cancer
 
Lung cancer
Lung cancerLung cancer
Lung cancer
 
Low dose ct lung cancer screening update
Low dose ct lung cancer screening updateLow dose ct lung cancer screening update
Low dose ct lung cancer screening update
 
Small cell carcinoma
Small cell carcinomaSmall cell carcinoma
Small cell carcinoma
 
CES2019-02: One hour on lung cancer for medical students
CES2019-02: One hour on lung cancer for medical studentsCES2019-02: One hour on lung cancer for medical students
CES2019-02: One hour on lung cancer for medical students
 
lung cancer
lung cancer lung cancer
lung cancer
 
Athanasios Andriopoulos_final (2)
Athanasios Andriopoulos_final (2)Athanasios Andriopoulos_final (2)
Athanasios Andriopoulos_final (2)
 
Lung cancer
Lung cancerLung cancer
Lung cancer
 
Cancer
CancerCancer
Cancer
 
CES2017-02: Lung Cancer
CES2017-02: Lung CancerCES2017-02: Lung Cancer
CES2017-02: Lung Cancer
 
Cancer - Dr.Rahul Shrivastava
Cancer - Dr.Rahul ShrivastavaCancer - Dr.Rahul Shrivastava
Cancer - Dr.Rahul Shrivastava
 
Lung_cancer_presentation.pptx for medical Surgical Nursing
Lung_cancer_presentation.pptx for medical Surgical NursingLung_cancer_presentation.pptx for medical Surgical Nursing
Lung_cancer_presentation.pptx for medical Surgical Nursing
 
CES2018-02: Cáncer de pulmón (clases 1 y 2)
CES2018-02: Cáncer de pulmón (clases 1 y 2)CES2018-02: Cáncer de pulmón (clases 1 y 2)
CES2018-02: Cáncer de pulmón (clases 1 y 2)
 

Lung cancer infographic

  • 1. THE CHANGING FACE OF LUNG CANCER IN 2013 LUNG CANCER ACCOUNTS FOR 14% of all new cancer cases1 ABOUT 228,190 NEW CASES OF LUNG CANCER WILL BE DIAGNOSED1 About 2 out of 3 people diagnosed with lung cancer are 65 or older1 Fewer than 2% of all cases are found in people younger than 451 118,080 men THE AVERAGE AGE AT THE 1 TIME OF DIAGNOSIS IS ABOUT THERE WILL BE AN ESTIMATED 159,480 DEATHS FROM LUNG CANCER1 Accounting for 27% of all cancer deaths1 110,110 women 71.1 THERE ARE 2 TYPES OF LUNG CANCER Non-small cell lung cancer (NSCLC): About 85-90% of lung cancers1 Small cell lung cancer (SCLC): About 10% to 15% of lung cancers1 References: 1. American Cancer Society. Lung Cancer (Non-Small Cell). Available at: http://www.cancer.org/cancer/lungcancer-non-smallcell/detailedguide/non-small-cell-lung-cancer-key-statistics. Last Accessed March 1, 2013. OC553716PRB